Active Substance: Vildagliptin.
Overview
Welcome to Dwaey, specifically on JALRA 50 page.
This medicine contains an important and useful components, as it consists of
Vildagliptinis available in the market in concentration
Vildagliptin
Patient w/ cardiac failure (NYHA functional class IV), type 1 DM; history of acute pancreatitis. Not intended for the treatment of diabetic ketoacidosis. Hepatic impairment, including patients w/ pre-treatment ALT or AST >3 times the upper limit of normal (ULN). Moderate or severe renal impairment, ESRD. Monitoring Parameters Monitor liver function.
Type 2 DM
Hypersensitivity to vildagliptin
Nausea, peripheral oedema, headache, tremor, asthenia, dizziness, constipation, hypoglycaemia, arthralgia, hepatic dysfunction, nasopharyngitis, upper resp tract infection, pancreatitis, exfoliative and bullous skin reactions.
0
Vildagliptin is a dipeptidylpeptidase-4 (DPP-4) inhibitor that improves glycaemic control by preventing DPP-4 from inactivating the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thus prolonging incretin activity in response to ingestion of nutrients. This increases insulin sensitivity, decreases glucagon secretion and improves ?-cell function.
Decreased hypoglycaemic effect w/ thiazides, corticosteroids, thyroid products and sympathomimetics.
Information not available